Last reviewed 2026-04-23 · How we verify

NIK-333(peretinoin)

Kowa Company, Ltd. · Phase 3 active Small molecule

NIK-333(peretinoin) is a retinoid Small molecule drug developed by Kowa Company, Ltd.. It is currently in Phase 3 development for Hepatocellular carcinoma.

NIK-333 (peretinoin) is a synthetic retinoid that acts as a retinoic acid receptor agonist.

NIK-333 (peretinoin) is a synthetic retinoid that acts as a retinoic acid receptor agonist. Used for Hepatocellular carcinoma.

At a glance

Generic name	NIK-333(peretinoin)
Sponsor	Kowa Company, Ltd.
Drug class	retinoid
Target	retinoic acid receptor
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 3

Mechanism of action

Peretinoin binds to retinoic acid receptors, influencing gene expression and potentially inhibiting tumor growth. This mechanism is thought to contribute to its therapeutic effects in various cancers.

Approved indications

Hepatocellular carcinoma

Common side effects

Hepatotoxicity

Key clinical trials

Study of Peretinoin for Suppressing Recurrence of HCV-positive HCC (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NIK-333(peretinoin) CI brief — competitive landscape report
NIK-333(peretinoin) updates RSS · CI watch RSS
Kowa Company, Ltd. portfolio CI

Frequently asked questions about NIK-333(peretinoin)

What is NIK-333(peretinoin)?

NIK-333(peretinoin) is a retinoid drug developed by Kowa Company, Ltd., indicated for Hepatocellular carcinoma.

How does NIK-333(peretinoin) work?

NIK-333 (peretinoin) is a synthetic retinoid that acts as a retinoic acid receptor agonist.

What is NIK-333(peretinoin) used for?

NIK-333(peretinoin) is indicated for Hepatocellular carcinoma.

Who makes NIK-333(peretinoin)?

NIK-333(peretinoin) is developed by Kowa Company, Ltd. (see full Kowa Company, Ltd. pipeline at /company/kowa-company-ltd).

What drug class is NIK-333(peretinoin) in?

NIK-333(peretinoin) belongs to the retinoid class. See all retinoid drugs at /class/retinoid.

What development phase is NIK-333(peretinoin) in?

NIK-333(peretinoin) is in Phase 3.

What are the side effects of NIK-333(peretinoin)?

Common side effects of NIK-333(peretinoin) include Hepatotoxicity.

What does NIK-333(peretinoin) target?

NIK-333(peretinoin) targets retinoic acid receptor and is a retinoid.

Drug class: All retinoid drugs
Target: All drugs targeting retinoic acid receptor
Manufacturer: Kowa Company, Ltd. — full pipeline
Therapeutic area: All drugs in Oncology
Indication: Drugs for Hepatocellular carcinoma